News
The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.
The Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) was terminated in April. After sweeping cuts ...
AGC Biologics has collaborated with Quell Therapeutics to advance the development of several T-regulatory (Treg) cell therapy ...
US President Donald Trump has resurrected a drug pricing plan that equates to International Reference Pricing.
Experts predict growing pains as the life sciences sector moves to adapt to the EU AI Act. The EU Artificial Intelligence (AI ...
The executive order instructs the FDA to expedite the approval process for domestic pharmaceutical manufacturing facilities.
Pathos AI has raised $365m in a Series D funding round to widen its AI-enabled platform to advance the development of ...
The US Food and Drug Administration has granted approval to Amneal Pharmaceuticals’ Brekiya (dihydroergotamine (DHE) mesylate ...
Artificial Intelligence (AI) is now used throughout clinical trials, from recruitment to analysis – but are regulators ...
The FDA approved 19 biosimilars in 2024, a sharp jump from the five greenlit by the agency in 2023. 2024 saw the highest ...
Boehringer Ingelheim has entered a multi-year partnership with Tempus AI to progress its cancer treatment pipeline.
Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results